Clinical ResultsORIC-114 has shown promising early clinical activity in NSCLC with EGFR/HER2 Ex20Ins and atypical mutations, with no severe adverse events at the target dose, indicating a strong safety profile.
Management And Financial StabilityA highly experienced management team with a successful track record, alongside a strong balance sheet, positions ORIC well for advancing clinical trials and strategic growth.
Strategic PartnershipsCollaboration with OpenBench aims to leverage AI-enabled discovery to enhance early research efforts, granting ORIC full rights to discovered leads and access to advanced screening technology.